Global Lung Cancer Therapeutics Market 2016-2020


#877716

101pages

Technavio

$ 2500

In Stock

About Lung Cancer Therapeutics
Lung cancer is a common cause of mortality and morbidity in both developed and developing countries. Smoking is a major cause of lung cancer, though it also occurs in non-smokers. Lung cancer can be categorized into two major types, namely NSCLC and SCLC. NSCLC is the commonest type of lung cancer and constitutes almost 85%-90% of the total diagnosed cases. It grows and spreads quite slowly.

Technavios analysts forecast the global lung cancer therapeutics market to contribute around $11.19 billion during the period 2016-2020.

Covered in this report
The report covers the present scenario and the growth prospects of the global lung cancer therapeutics market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent lung cancer therapeutics. The report also considers the revenues to be generated from the sales of drugs that are expected to be launched into the market along with the decline in revenues from the genericization of the marketed drugs during the forecast period.

The market is divided into the following segments based on geography:
Americas
APAC
EMEA

Technavio's report, Global Lung Cancer Therapeutics Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
F. Hofmann-La Roche
Eli Lilly
AstraZeneca
Pfizer
Celgene

Other prominent vendors
Abbvie
Aetna
Agennix
Allergan
Amgen
ARIAD Pharmaceuticals
Astellas Pharma
Betta Pharmaceuticals
BeyondSpring Pharmaceuticals
BioNumerik Pharmaceuticals
Boehringer Ingelheim
Boston Biomedical
Bristol-Myers Squibb
Celldex
CTI BioPharma
Eisai
GlaxoSmithKline
GTx
Helsinn
Hutchison Medipharma
Ionis Pharmaceuticals
Kadmon Corporation
MabVax
Merck
Novartis
NovaRx Corporation
OncoGeneX
Ono Pharmaceutical
OSE Immunotherapeutics
OSI Pharmaceuticals
Peregrine
PharmaMar
Pierre Fabre
Qiagen
Recombio
Samsung Bioepis
Sanofi
SFJ Pharmaceuticals
Spectrum Pharmaceuticals
Sumitomo Dainippon Pharma
Synta
Takeda Pharmaceuticals
Teva Pharmaceutical
Xcovery

Market driver
Growing demand for targeted therapies
For a full, detailed list, view our report

Market challenge
Growing popularity of alternative therapeutics
For a full, detailed list, view our report

Market trend
Emergence of nanomedicine platform for the treatment of lung cancer
For a full, detailed list, view our report

Key questions answered in this report
What will the market size be in 2020 and what will the growth rate be?
What are the key market trends?
What is driving this market?
What are the challenges to market growth?
Who are the key vendors in this market space?
What are the market opportunities and threats faced by the key vendors?
What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.